StocksMedium•10 November 2026•
1 min read
Anupam Rasayan Revenue Grows 21% in H1 FY27 Amid Margin Expansion
Key Facts
1Anupam Rasayan reported a 21% year-on-year increase in consolidated revenue to INR 1,489 crore for H1 FY27.
2EBITDA rose 38% to INR 377 crore, with EBITDA margins improving to 25% in Q2 FY27.
3Management guided to a consolidated EBITDA margin of 22% to 24% following the Bliss GVS Pharma acquisition.
Anupam Rasayan reported a 21% year-on-year increase in consolidated revenue to INR 1,489 crore for the first half of fiscal year 2027. Yahoo Finance reported that EBITDA rose 38% to INR 377 crore, as EBITDA margins improved to 25% during the second quarter.
Management guided to a consolidated EBITDA margin of 22% to 24% for the upcoming period. This outlook follows the integration of the Bliss GVS Pharma acquisition, which has contributed to the company's operational performance and margin expansion within the chemical sector.